<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914809</url>
  </required_header>
  <id_info>
    <org_study_id>2010-A00633-36</org_study_id>
    <secondary_id>2010-04</secondary_id>
    <nct_id>NCT01914809</nct_id>
  </id_info>
  <brief_title>Micro Array Analysis in Preeclampsia</brief_title>
  <official_title>Micro Array Analysis in Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia is a frequent pathology. His etiology is doubtful.&#xD;
&#xD;
      Targets :&#xD;
&#xD;
      The study target is to identify a risk of preeclampsia group obtained with transcriptom&#xD;
      analysis from circulating peripheric cells.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Multidisciplinary study (Gynaecology-Obstetric, Immunology, North CIC).&#xD;
&#xD;
      The study of the transcriptional history of peripheral blood cells of 2patients groups:&#xD;
&#xD;
        -  A patient group with a preeclampsia before 34 SA&#xD;
&#xD;
        -  A patient group with a normal pregnancy paired on main confusion factors. Blood sampling&#xD;
           will be collected at the diagnosis and 8 weeks after delivery.&#xD;
&#xD;
      Results and perspectives&#xD;
&#xD;
        -  Obtain a transcriptionnal signature of preeclampsia&#xD;
&#xD;
        -  To identify new mechanism of the disease&#xD;
&#xD;
        -  Identification of a specific transcriptom analysis with the comparison after delivery&#xD;
           For long-term, the target is to identify risk patient in order to conduct easily&#xD;
           preventive clinical trials in preeclamsia (primary prevention) and to consider a&#xD;
           specific follow-up for risk patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2011</start_date>
  <completion_date type="Anticipated">January 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>predictive markers of preeclampsia</measure>
    <time_frame>36 months</time_frame>
    <description>blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>analysis of placental transcriptional profile.</measure>
    <time_frame>36 months</time_frame>
    <description>biopsie placentaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>group with a preeclampsia before 34 SA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group with a normal pregnancy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>samples blood</intervention_name>
    <arm_group_label>group with a normal pregnancy</arm_group_label>
    <arm_group_label>group with a preeclampsia before 34 SA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biopsy placentaire</intervention_name>
    <arm_group_label>group with a normal pregnancy</arm_group_label>
    <arm_group_label>group with a preeclampsia before 34 SA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A prééclampsie (blood pressure superior to 140 mmHg and to 90 mmHg) and at least a&#xD;
             cross of protein in the strip and/or more of 300mg / 24h after 20 LIMITED COMPANIES&#xD;
             and before 34 limited companies.&#xD;
&#xD;
          -  An informed consent signed by the patient will necessarily have to be obtained.&#xD;
&#xD;
          -  Woman having been taken care during the pregnancy or at the time of the&#xD;
             childbirth(delivery) by one of the participating teams to the current project.&#xD;
&#xD;
          -  Caucasian Patient&#xD;
&#xD;
          -  Wait primigeste and nullipare&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major Patient protected by the law.&#xD;
&#xD;
          -  Patient deprived of freedom for administrative or judicial reasons.&#xD;
&#xD;
          -  Patient not benefiting from a national insurance scheme.&#xD;
&#xD;
          -  Refusal of the patient to participate in the study.&#xD;
&#xD;
          -  Not Caucasian Patient&#xD;
&#xD;
          -  Multipare Wait&#xD;
&#xD;
          -  Multiple Pregnancy&#xD;
&#xD;
          -  Existence of foetal deformation explaining a delay of growth or a foetal death in&#xD;
             utero.&#xD;
&#xD;
          -  Age 18 years and &gt; 40 years.&#xD;
&#xD;
          -  Absence of written consent or impossibility to receive the written consent (language&#xD;
             or understanding).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOIC MONDOLONI</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>florence bretelle</last_name>
    <email>florence.bretelle@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>florence bretelle</last_name>
      <email>florence.bretelle@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>florence bretelle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 11, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

